Crohn's Disease Clinical Trials

If you are living with Crohn’s, our clinical research study may be for you. Our team of medical professionals is evaluating an oral investigational drug called filgotinib to see if it reduces the signs and symptoms of Crohn’s disease by lowering the immune response that causes inflammation in the digestive ...

Is your Crohn's Disease not Properly Controlled by Medication? Wake Research Associates is currently enrolling a research study, testing the safety and effectiveness of investigational doses of an already-approved medicine in individuals with moderate to severe Crohn's disease.

A study to evaluate the safety and efficacy of an investigational drug in subjects with moderate to severe Crohn's disease. REF: 001-CGI

Join a clinical research study of Crohn’s disease. Wake Research Associates is enrolling volunteers with Crohn’s disease in a study evaluating the effectiveness of a nutritional intervention in improving bowel health when combined with usual medical care.

Do you suffer from Crohn’s Disease? Wake Research Associates is enrolling volunteers with Crohn’s in a clinical research study of an investigational medication.

Wake Research Associates is looking for volunteers for a research study of an investigational drug for moderate to severe Crohn’s disease. The study will test the drug’s safety and effectiveness.

Local doctors are looking for people with Crohn's disease for clinical research studies of an investigational medication. Compensation provided for time and travel!  

Do you suffer from moderate to severe Crohn’s disease? If so, you may qualify for a clinical trial. ClinSearch is testing the safety and effectiveness of an investigational medication for individuals with moderate to severe Crohn’s disease.

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at ...

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis ...